Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $0.39, $0.04 better than the analyst estimate of $0.35. Revenue for the quarter came in at $514 million versus the consensus estimate of $487.49 million.

Vertex reiterates 2017 guidance for ORKAMBI and KALYDECO product revenues; updates guidancefor combined GAAP and non-GAAP R&D and SG&A expenses

"During the first half of 2017, Vertex has made significant progress throughout the business and in particular, across our CF development programs," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "Our progress has been marked by the progression of multiple combination regimens that allow us to treat more people with CF today and to potentially treat up to 90% of patients with this disease in the future."

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.